The Liver Meeting

The Liver Meeting

Source:

Hirschfield G, et al. ENHANCE: Safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC) - A phase 3 international, randomized, placebo-controlled study. Presented at: The Liver Meeting Digital Experience; Nov. 13-16, 2020.

Disclosures: Hirschfield reports financial relationships with CymaBay Therapeutics, Falk Pharma Genfit, GSK, Intercept, Morphic Therapeutic, Mirum, Pliant and Roche.
November 25, 2020
1 min watch
Save

VIDEO: Seladelpar safe, well-tolerated in patients with primary biliary cholangitis

Source:

Hirschfield G, et al. ENHANCE: Safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC) - A phase 3 international, randomized, placebo-controlled study. Presented at: The Liver Meeting Digital Experience; Nov. 13-16, 2020.

Disclosures: Hirschfield reports financial relationships with CymaBay Therapeutics, Falk Pharma Genfit, GSK, Intercept, Morphic Therapeutic, Mirum, Pliant and Roche.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this exclusive video, Gideon Hirschfield, FRCP, PhD, from the Toronto Centre for Liver Disease, University of Toronto, discussed results from the ENHANCE study of seladelpar for treating patients with primary biliary cholangitis.

Hirschfield, who is also the Lily and Terry Horner Chair in Autoimmune Liver Disease Research, said seladelpar (CymaBay Therapeutics) was safe and well-tolerated by patients. He reported 10 mg of seladelpar was better than 5 mg and will be further studied in other clinical trials. Additionally, seladelpar significantly reduced pruritis.